Table 1.
Background characteristics of HIV-negative individuals and people living with HIV (PLWH) who had received at least one dose of SARS-CoV-2 vaccine.
| People Living with HIV (n = 129) |
HIV-Negative Individuals (n = 53) |
p Values | |
|---|---|---|---|
| Socio-Demographics | |||
| Age (years), n (%) | |||
| 18–29 | 39 (30.2) | 14 (26.4) | |
| 30–39 | 65 (50.4) | 19 (35.8) | |
| 40–49 | 20 (15.5) | 11 (20.8) | |
| 50–59 | 5 (3.9) | 9 (17.0) | 0.01 |
| Median (IQR), range | 34 (28, 38) (20–58) |
34 (29, 47) (22–56) |
0.15 |
| Gender, n (%) | |||
| Male | 128 (99.2) | 40 (75.5) | |
| Female | 1 (0.8) | 13 (24.5) | <0.001 |
| Presence of chronic conditions other than HIV/AIDS | |||
| No | 102 (79.1) | 53 (100.0) | |
| Yes | 27 (20.9) | 0 (0.0) | <0.001 |
| Characteristics related to HIV infection | |||
| Time since HIV diagnosis (years) | |||
| ≤1 | 18 (14.0) | N.A | N.A. |
| 2–5 | 55 (42.6) | N.A | N.A. |
| 6–10 | 35 (27.1) | N.A | N.A. |
| >10 | 21 (16.3) | N.A | N.A. |
| Viral load (cp/mL), n (%) | |||
| Undetectable (≤60) | 75 (58.1) | N.A. | N.A. |
| 61–200 | 33 (25.6) | N.A. | N.A. |
| >200 | 21 (16.3) | N.A. | N.A. |
| Median (IQR), range | 41 (0, 117) (0, 50397) |
N.A. | N.A. |
| CD4+ T-cell count (cells/μL) | |||
| <500 | 32 (24.8) | N.A. | N.A. |
| 500–1000 | 81 (62.8) | N.A. | N.A. |
| >1000 | 16 (12.4) | N.A. | N.A. |
| Median (IQR), range | 630.5 (499.5, 848.8) (78, 2650.35) |
N.A. | N.A. |
| ART regimens | |||
| TDF + 3TC + EFV | 60 (52.7) | N.A. | N.A. |
| TDF + 3TC + LPV/r | 5 (3.9) | N.A. | N.A. |
| AZT + 3TC + LPV/r | 3 (2.3) | N.A. | N.A. |
| AZT + 3TC + NVP | 2 (1.6) | N.A. | N.A. |
| AZT + 3TC + EFV | 8 (6.2) | N.A. | N.A. |
| Others | 40 (31.0) | N.A. | N.A. |
| Not on ART | 3 (2.3) | N.A. | N.A. |
| Information related to SARS-CoV-2 vaccination | |||
| SARS-CoV-2 vaccination status | |||
| Partially vaccinated | 35 (27.1) | 2 (3.8) | |
| 0–14 days since fully vaccinated | 15 (11.6) | 8 (15.1) | |
| 15–28 days since fully vaccinated | 38 (29.5) | 13 (25.5) | |
| 29–56 days since fully vaccinated | 26 (20.2) | 21 (39.6) | |
| 57–84 days since fully vaccinated | 12 (9.3) | 3 (5.7) | |
| >84 days since fully vaccinated | 3 (2.3) | 8 (15.1) | <0.001 |
| Type of SARS-CoV-2 vaccine | |||
| Sinopharm | 58 (45.0) | 37 (69.8) | |
| Sinovac CoronaVac | 71 (55.0) | 16 (30.2) | <0.001 |
| Time interval between the first and second dose (among those who were fully vaccinated) | n = 94 | n = 51 | |
| <21 days | 20 (21.3) | 3 (5.7) | |
| 21–28 days | 58 (61.7) | 40 (75.5) | |
| >28 days | 16 (17.0) | 10 (18.9) | 0.043 |
| Median (IQR), range | 21 (21, 27) (14–59) |
27 (21, 28) (14–83) |
0.002 |
N.A.: not applicable.